Algert Global LLC Sells 5,570 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Algert Global LLC decreased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 14.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,117 shares of the company’s stock after selling 5,570 shares during the quarter. Algert Global LLC’s holdings in Fulcrum Therapeutics were worth $160,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. MetLife Investment Management LLC raised its holdings in shares of Fulcrum Therapeutics by 145.8% in the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company’s stock valued at $189,000 after buying an additional 23,792 shares during the last quarter. Barclays PLC increased its position in Fulcrum Therapeutics by 367.1% in the 3rd quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after acquiring an additional 97,565 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock worth $567,000 after acquiring an additional 6,770 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Fulcrum Therapeutics by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock worth $161,000 after purchasing an additional 8,761 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Fulcrum Therapeutics by 176.8% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock valued at $1,728,000 after purchasing an additional 234,810 shares during the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.71.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC opened at $5.79 on Wednesday. The company has a 50 day moving average of $3.48 and a 200-day moving average of $3.73. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $10.13. The stock has a market cap of $312.54 million, a price-to-earnings ratio of -18.68 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. Equities research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.